Literature DB >> 25597615

Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus.

Hejun Li1, Shunping Lin, Shangchih Yang, Ling Chen, Xiangxiong Zheng.   

Abstract

In 2009, hypocomplementemia involving C3, C4, and total hemolytic complement (CH50) was proposed as an immunologic criterion to enhance the sensitivity of systemic lupus erythematosus (SLE) classification criteria. This study evaluated the diagnostic value of low serum complement C3 and C4 levels in Chinese patients with SLE. In total, 2452 patients were enrolled in this study (158 with SLE and 2294 with other diseases). Receiver operating characteristic analysis showed that the optimal C3 and C4 cut-off levels for a diagnosis of SLE were 0.785 g/L (sensitivity, 77.9%; specificity, 81.5%) and 0.145 g/L (sensitivity, 80.1%; specificity, 83.2%), respectively. The prevalence of a low C3 or C4 level alone was similar between patients with SLE and those with other diseases, while the prevalence of simultaneously low C3 and C4 levels was higher in patients with SLE (73.42%). Antinuclear antibody had a high sensitivity (96.64%) and low negative likelihood ratio (0.04). Hypocomplementemia with positive antinuclear antibody had a high positive likelihood ratio. Inclusion of hypocomplementemia as a classification criterion for SLE resulted in a 16.18% increase in the number of patients assigned to the SLE group (from 136 to 158 patients). Hypocomplementemia was highly prevalent in patients with hematological disease (41.94%). These results suggest that hypocomplementemia has important diagnostic value for SLE by improving the sensitivity of the diagnosis of SLE. C3 and C4 should be tested simultaneously because a low C3 or C4 level alone is not a suitable immunological criterion.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25597615     DOI: 10.1007/s10067-014-2843-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.

Authors:  Heikki Julkunen; Susanne Ekblom-Kullberg; Aaro Miettinen
Journal:  Rheumatol Int       Date:  2011-06-26       Impact factor: 2.631

3.  Noncalcified coronary plaque in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Jens Vogel-Claussen; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2010-01-28       Impact factor: 4.666

4.  The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus.

Authors:  Megan E B Clowse; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2011-03-16       Impact factor: 4.666

Review 5.  The search for lupus biomarkers.

Authors:  Chau-Ching Liu; Joseph M Ahearn
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-08       Impact factor: 4.098

6.  Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations.

Authors:  E F Borba; D B Araujo; E Bonfá; S K Shinjo
Journal:  Lupus       Date:  2013-05-17       Impact factor: 2.911

7.  Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.

Authors:  Juan Li; Lemei An; Zhuoli Zhang
Journal:  Clin Exp Rheumatol       Date:  2013-08-26       Impact factor: 4.473

8.  Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members.

Authors:  Benjamin F Bruner; Joel M Guthridge; Rufei Lu; Gabriel Vidal; Jennifer A Kelly; Julie M Robertson; Diane L Kamen; Gary S Gilkeson; Barbara R Neas; Morris Reichlin; R Hal Scofield; John B Harley; Judith A James
Journal:  Arthritis Rheum       Date:  2012-11

9.  Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group.

Authors:  D M Ricker; L A Hebert; R Rohde; D D Sedmak; E J Lewis; J D Clough
Journal:  Am J Kidney Dis       Date:  1991-12       Impact factor: 8.860

10.  Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital.

Authors:  Paul Etau Ekwom
Journal:  Clin Rheumatol       Date:  2013-03-03       Impact factor: 3.650

View more
  8 in total

1.  The clinical characteristics of low C4 alone in patients with systemic lupus erythematosus.

Authors:  Weiji Xie; Zeen Xiao; Jing Xu; Guitian Hong; Xiaochang Xu; Yimin Zhang; Xialan Zhang
Journal:  Clin Rheumatol       Date:  2020-08-27       Impact factor: 2.980

Review 2.  Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.

Authors:  Sara K Tedeschi; Sindhu R Johnson; Dimitrios Boumpas; David Daikh; Thomas Dörner; David Jayne; Diane Kamen; Kirsten Lerstrøm; Marta Mosca; Rosalind Ramsey-Goldman; Corine Sinnette; David Wofsy; Josef S Smolen; Raymond P Naden; Martin Aringer; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-22       Impact factor: 4.794

3.  Urinary interleukin 22 binding protein as a marker of lupus nephritis in Egyptian children with juvenile systemic lupus erythematosus.

Authors:  Ahmed Mohamed Mahmoud Badr; Yomna Farag; Maie Abdelshafy; Nermine Magdi Riad
Journal:  Clin Rheumatol       Date:  2017-09-09       Impact factor: 2.980

4.  Pseudo-pseudo Meigs' syndrome presenting with a combination of polyserositis, elevated serum CA 125 in systemic lupus erythematosus: A case report.

Authors:  Fei Gao; YongMei Xu; GuoWang Yang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

5.  Total Serum Calcium Level Is Negatively Correlated With Systemic Lupus Erythematosus Activity.

Authors:  Yeqin Sha; Zhilian Rui; Yuxiang Dong; Xiyi Wei; Yuning Zhou; Xiaoxue Ye; Lianping He; Dongyan Shi
Journal:  Dose Response       Date:  2020-05-13       Impact factor: 2.658

Review 6.  Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus.

Authors:  Haitao Yu; Yasuo Nagafuchi; Keishi Fujio
Journal:  Biomolecules       Date:  2021-06-22

7.  Systemic lupus erythematosus presenting with progressive massive ascites and CA-125 elevation indicating Tjalma syndrome? A case report.

Authors:  Jun-Di Wang; Yan-Fei Yang; Xian-Feng Zhang; Jiao Huang
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

8.  Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis.

Authors:  Tatiana Koudriavtseva; Annunziata Stefanile; Marco Fiorelli; Caterina Lapucci; Svetlana Lorenzano; Silvana Zannino; Laura Conti; Giovanna D'Agosto; Fulvia Pimpinelli; Enea Gino Di Domenico; Chiara Mandoj; Diana Giannarelli; Sara Donzelli; Giovanni Blandino; Marco Salvetti; Matilde Inglese
Journal:  Front Immunol       Date:  2020-10-27       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.